Novel synthetic, salt-resistant analogs of human beta-defensins 1 and 3 endowed with enhanced antimicrobial activity

O Scudiero, S Galdiero, M Cantisani… - Antimicrobial agents …, 2010 - Am Soc Microbiol
O Scudiero, S Galdiero, M Cantisani, R Di Noto, M Vitiello, M Galdiero, G Naclerio…
Antimicrobial agents and chemotherapy, 2010Am Soc Microbiol
Human beta-defensins (hBDs) are antimicrobial peptides of human innate immunity. The
antibacterial activities of hBDs 1, 2, and 4 but not the activity of hBD3 are impaired by high
salt levels. We have designed and synthesized seven novel hBD analogs, constituted by
different domains of hBD1 (which is constitutively expressed in humans) and of hBD3 (which
is induced by microorganisms and inflammatory factors in humans), that would maintain and
potentially increase the wild-type antimicrobial activities and be salt resistant. We have …
Abstract
Human beta-defensins (hBDs) are antimicrobial peptides of human innate immunity. The antibacterial activities of hBDs 1, 2, and 4 but not the activity of hBD3 are impaired by high salt levels. We have designed and synthesized seven novel hBD analogs, constituted by different domains of hBD1 (which is constitutively expressed in humans) and of hBD3 (which is induced by microorganisms and inflammatory factors in humans), that would maintain and potentially increase the wild-type antimicrobial activities and be salt resistant. We have compared the antibacterial, antiviral, and chemotactic activities of the analogs with those of hBD1 and hBD3. We show that the hBD1 internal region and the hBD3 C-terminal region are critical for antibacterial activity also at high salt concentrations, whereas deletion of the N-terminal region of hBD3 results in an increase in antibacterial activity. All analogs inhibited herpes simplex virus; antiviral activity was enhanced by the hBD1 internal region and the hBD3 C-terminal region. Wild-type and analog peptides were chemotactic for granulocytes and monocytes, irrespective of the salt concentrations. These new peptides may have therapeutic potential.
American Society for Microbiology